U
University of California, Los Angeles | UCLA Doheny Eye Center
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
RPh201
Parent organization
This site is a part of University of California, Los Angeles
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 4 total trials
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...
Enrolling
Choroidal Neovascularization
Wet Age-related Macular Degeneration
Genetic: ABBV-RGX-314
Biological: Ranibizumab (LUCENTIS®)
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucom...
Enrolling
Open-Angle Glaucoma
Device: XEN45 (Glaucoma Gel Stent)
Trial sponsors
R
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems